Company |
Drug |
Indication |
Astellas Pharma Inc. (Tokyo) and Pfizer Inc. (New York) |
Xtandi |
Metastatic castration-resistant prostate |
Eli Lilly and Co. (Indianapolis) |
Lartruvo |
Soft tissue sarcoma |
Genentech Inc. (South San Francisco) |
Lucentis |
Wet age-related macular degeneration |
Genentech Inc. (South San Francisco; unit of Roche Holdings AG) |
Tecentriq |
Metastatic non-small-cell lung cancer |
Janssen Pharmaceuticals Inc. (Raritan, N.J.) |
Xarelto |
Atrial fibrillation |
Ligand Pharmaceuticals Inc. (San Diego) and Lundbeck A/S (Copenhagen) |
Carnexiv |
Seizures |
Merck & Co Inc. (Kenilworth, N.J.) |
Keytruda |
Non-small-cell lung cancer (NSCLC) |
Merck & Co. Inc. (Kenilworth, N.J.) |
Zinplava |
Clostridium difficile infection |
Orexo AB (Uppsala, Sweden) |
Zubsolv |
Opioid dependence |
Protein Sciences Corp. (Meriden, Conn.) |
Flublok |
Influenza |
Roche Holding AG (Basel, Switzerland) |
Ventana |
Metastatic non-small-cell lung cancer |